An abbreviated area-under-the-curve monitoring for tacrolimus in patients with liver transplants

Therapeutic Drug Monitoring

Volumn 20, Issue 2, 1998, Pages 219-223

  Ku, Yi Min ^a   Min, David I ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

AUC monitoring; Liver transplant; Tacrolimus

Indexed keywords

TACROLIMUS;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HUMAN; LIVER TRANSPLANTATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; AREA UNDER CURVE; CIRCADIAN RHYTHM; DRUG MONITORING; GRAFT REJECTION; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; LINEAR MODELS; LIVER TRANSPLANTATION; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; TACROLIMUS;

EID: 0031978471     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199804000-00014     Document Type: Article

References (20)

1. Hooks MA. Tacrolimus, a new immunosuppressant - a review of the literature. Ann Pharmacother 1994;28:501-11.
2. Kelly PA, Burckart GJ, Venkataramanan R. Tacrolimus: a new immunosuppressant. Am J Health-Syst Pharm 1995;52:1521-35.
3. Jusko WJ, Piekozewski W, Klintmalm GB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995;57:281-90.
4. Min DI, Chen H, Fabrega A, et al. Circadian variation of tacrolimus in liver transplant patients. Transplantation 1996;62:1190-2.
5. Min DI, Chen H, Lee M, Ashton K, Martin M. Time-dependent disposition of tacrolimus and endothelin-1 in the liver transplant. Pharmacotherapy 1997;17:457-63.
6. Tacrolimus package insert, Fujisawa, Deerfield, IL, U.S.A., 1996.
7. The U.S. multicenter FK 506 liver study group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994;331:1110-5.
8. European FK 506 multicenter liver study group. Randomised trial comparing tacrolimus (FK 506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994;44:423-8.
9. Jusko WJ, Thomson AW, Fung J, et al. Consensus document: therapeutic monitoring of tacrolimus (FK506). Ther Drug Monit 1995:17:606-14.
10. Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996;62:920-6.
11. Takahara S, Kokado Y, Kameoka H, et al. Monitoring of FK506 blood levels in kidney transplant recipients. Transplant Proc 1994; 26:2106-8.
12. Winkler M, Ringe B, Rodeck B, et al. The use of plasma levels for FK506 dosing in liver-graft patients. Transpl Int 1994;7:329-33.
13. Backman L, Nicar M, Levy M, et al. FK506 trough levels in whole blood and plasma in liver transplant recipients: correlation with toxicity. Transplant Proc 1994;26:1804.
14. Erden E, Warty V, Magnone M, Shapiro R, Demetris J, Randhawa P. Plasma FK506 levels in patients with histopathologically documented renal allograft rejection (letter). Transplantation 1994;58: 397.
15. Kahan BD, Welth M, Rutzky L. Challenges in cyclosporine therapy: the role of therapeutic monitoring by area under the curve monitoring. Ther Drug Monit 1995;17:621-4.
16. Kahan BD, Welth M, Rutzky L, et al. The ability of pretransplant test-dose pharmacokinetic profiles to reduce early adverse events after renal transplantation. Transplantation 1992;53:345-51.
17. Grevel J, Kahan BD. Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy. Clin Chem 1991;37: 1905-8.
18. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993;54:205-18.
19. Transplant Diagnostics for Tacrolimus Assay. Abbott Park, IL: Abbott Laboratories, Diagnostics Division, 1993.
20. Meyer MM, Munar M, Udeaja J, Bennett W. Efficacy of area under the curve cyclosporine monitoring in renal transplantation. J Am Soc Nephrol 1993;4:1306-15.